Type 2 inflammation and biologics: a twenty-year journey

Over the past two decades, targeted biological therapies have profoundly transformed the management of type 2 (T2) inflammatory diseases, including severe asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic spontaneous urticaria, and eosinophilic granulomatosis with polyangiitis. This paper reviews the key milestones of this twenty-year journey, focusing on the evolving therapeutic goals, from disease control to clinical remission.

This paper synthesizes evidence from pivotal clinical trials, real-world registries, extension studies, and systematic reviews on biologics in T2 inflammatory diseases. A targeted literature search was conducted across PubMed and major respiratory, allergy, and dermatology journals, prioritizing publications from 2020 to 2026, with inclusion of landmark earlier studies.

Clinical remission in biologic-treated T2 inflammatory diseases is achievable but not yet reliably predictable; the field urgently requires globally standardized, validated composite remission indices for each major T2 condition that integrate symptom scores, organ function measures, and biomarker profiles. The defining challenge of the next decade is determining whether early biologic intervention can genuinely modify the disease trajectory and achieve sustained off-treatment remission.